Quinolones: A practical review of clinical uses, dosing considerations, and drug interactions

Journal of Family Practice

Volumn 42, Issue 1, 1996, Pages 69-78

  Borcherding, Shawn M ^a   Stevens, Robert ^b   Nicholas, Richard A ^c   Corley, Cheryl R ^b   Self, Timothy ^b  

^a PROCTER AND GAMBLE COMPANY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

ciprofloxacin; drug interactions; enoxacin; norfloxacin; ofloxacin; Quinolones

Indexed keywords

ANTACID AGENT; CAFFEINE; CIPROFLOXACIN; ENOXACIN; ISONIAZID; LOMEFLOXACIN; NORFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE; SUCRALFATE; THEOPHYLLINE; WARFARIN;

ABDOMINAL PAIN; BLEEDING; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GASTROINTESTINAL INFECTION; HEADACHE; HUMAN; NAUSEA; ORAL DRUG ADMINISTRATION; RESPIRATORY TRACT INFECTION; REVIEW; SEXUALLY TRANSMITTED DISEASE; SOFT TISSUE INFECTION; URINARY TRACT INFECTION; VERTIGO; VOMITING;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DRUG INTERACTIONS; FLUOROQUINOLONES; HUMANS; INTESTINAL ABSORPTION; LIVER; QUINOLONES;

EID: 0030031716     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991; 324:384-94.
2. Woltson JS, Hooper DC. Fluoroqtiinolone antimicrobial agnts. Clin Microbiol Rev 1989; 2:378-424.
3. Chysky V, Kapila K, Hullmann R, et al. Safety of ciprofloxacin in children, world-wide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection 1991; 9:289.
4. Hooper DC. Quinolones. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. New York, NY: Churchill Livingstone, 1995.364-76.
5. Raz R, Boger S. Long-term prophylaxis with norfloxacin versus nitrofurantoin in women with recurrent urinary tract infection. Antimicrob Agents Chemother 1991; 35:1241
6. Wolfson JS, Hooper DC. Treatment of genitourinary tract infections with fluoroqumolones: activity in vitro, pharmacokuietics, and clinical efficacy in urinary tract infections and prostatitis. Antimicrob Agents Chemother 1989; 33:1655.
7. Lee BL, Padula AM, Kimbrough RC, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991; 325:520.
8. Frieden TR, Mangi RJ. Inappropriate, use of oral ciprofloxacin. JAMA 1990; 264.1438.
9. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994; 38: 547
10. Peloquin CA, Cambo TJ, Nix DE, et al. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: impact of plasma concentrations, organisms, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med 1989, 149:2269.
11. Thornsberry C. Trends in antimicrobial resistance among today's bacterial pathogens. Pharmacotherapy 1995; 15.3S-8S.
12. Drancourt M, Stem A, Argenson JN, et al Oral rifampin plus ofloxacin for treatment of Staphylacoccus-infceted orthopedic implants. Antimicrob Agents Chemother 1993, 37-1214.
13. Gentry LO. Review of quinolones in treatment of infections of the skin and skin structure. J Antimicrob Chemother 1991; 28 (suppl C):97-110.
14. DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993; 328:1821-7
15. DuPont HL. Travellers' diarrhea. Which antimicrobial? Drugs 1993; 45:910-7.
16. Nightingale CH. Pharmacokinetic considerations in quinolone therapy. Pharmacotherapy 1993; 13:34S-38S.
17. Honeybourne D, Wise R, Andrews JM Ciprofloxacin penetration into lungs. Lancet 1987; 1:1040
18. Flor S. Pharmacokinetics of ofloxacin. Am J Med 1989; 87 (suppl 6C) 24S-30S.
19. Swan SK, Bennett WM. Drug dosing guidelines in patients with renal failure. West J Med 1992; 156:633-8.
20. Norrby R, Lietman PA. Safety and tolerability of fluoroquinolones. Drugs 1993; 45:59-64.
21. Finch RG. The withdrawal of temafloxacin. Are there implications for other quinolones? Drug Safety 1993; 8:9-11.
22. Hori S, Shimada J. Effects of quinolones on the central nervous system. In: Hooper DC, Wolfson JS, eds. Quinolone antimicrobial agents. 2nd ed. Washington DC: American Society for Microbiology, 1993:513-8.
23. Schwartz MT, Calvert JF: Potential neurologic toxicity related to ciprofloxacin. Ann Pharmacother 1990; 24:138-40.
24. Szarfman A, Chen M, Blum MD. More on fluroquinolone antibiotics and tendon rupture [letter] N Engl J Med 1995; 332:193.
25. Wijnands WJA, Vree TB, Van Herwaarden CLA. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 1986; 22:677-83.
26. Sano M, Kawakatsu K, Ohkita C, et al. Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans. Eur J Clin Pharmacol 1988; 35.161-5.
27. Schwartz J, Jauregul L, Letteiri J, Bachmann K. Impact of ciprofloxacin on theophylline clearance and steady state concentrations in serum. Antimicrob Agents Chemother 1988; 32-75-7
28. Prince RA, Casabar E, Adair CG, Wexler DE, Letteiri J, Kasik JE. Effect of quinolone antimicrobials on theophylline pharmacokinetics J Clin Pharmacol 1989; 29:650-4.
29. Ho G, Tierney MG, Dales RE. Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline. Clin Pharmacol Ther 1988; 44.35-8.
30. Davis RL, Kelly WH, Quenzer RW, Standefer J, Steinberg B, Gallegos J. Effect of norfloxacin on theophylline metabolism. Antimicrob Agents Chemother 1989; 33:212-4.
31. Gregoire SL, Grasela TH, Freer JP, Tack KJ, Schentahg JJ. Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects Antimicrob Agents Chemother 1987; 31:375-8.
32. Nix DE, Norman A, Schentag JJ. Effect of lomefloxacin on theophylline pharmacokinetics. Antimicrob Agents Chemother 1989; 33:1006-8.
33. LeBel M, Vallee F, St-Laurent M. Influence of lomefloxacin on the pharmacokinetics of theophylline. Antimicrob Agents Chemother 1990; 34:1254-6.
34. Grasela TH, Dreis MW An evaluation of the quinolone-theophyllinc interaction using the Food and Drug Administration spontaneous reporting system. Arch Intern Med 1992; 152:617-21.
35. Wijnands WFA, Herwaarden CLA, Vree TB. Enoxacin raises plasma theophylline concentrations. Lancet 1984; 2:108-9.
36. Takagi K, Hasegawa T, Yamaki, Suzuki R, Watanabe T, Satake T, Interaction between theopylline and enoxacin Int J Clin Pharmacol Ther Toxicol 1988; 26:288-92.
37. Peloquin CA, Nix DE, Sedman AJ, et al. Pharmacokinetics and clinical effects of caffeine alone and in combination with oral enoxacin. Rev Infect Dis 1989; 11 (suppl 5):1095.
38. Healy DP, Polk RE, Kanawaka L, Rock DT, Mooney ML. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother 1989; 33:474-8.
39. Staib AH, Stille W, Dictlein G, Shah PM, Harder S, Mieke S, et al. Interaction between quinolones and caffeine. Drugs 1987; 34:170-4.
40. Mott FE, Murphy S, Hunt V. Ciprofloxacin and warfarin [letter]. Ann Intern Med 1989; 111:542-3.
41. Linville D, Emory C, Graves L. Ciprofloxacin and warfarin interaction [letter]. Am J Med 1991; 90:765.
42. Kamada AK Possible interaction between ciprofloxacin and warfarin. Drug Intell Clin Pharm 1990; 24:27-8
43. Jolson HM, Tanner LA, Green L, Grasela TH Adverse reaction reporting of interaction between warfarin and fluoroquinolones. Arch Intern Med 1991; 151:1003-4.
44. Johnson KC, Joe RH, Self TH. Drug interaction [letter]. J Fam Pract 1991; 33:338.
45. Dugom-Kramer BM. Ciprofioxacin-warfarin interaction [letter]. Ann Pharmacother 1991; 25-1397.
46. Linville T, Matain D. Norfloxacin and warfarin [letter]. Ann Intern Med 1989; 110-751.
47. Leor J, Matetzki S. Ofloxacin and warfarin [letter]. Ann Intern Med 1988; 109:761.
48. Baciewicz AM, Ashar BH, Locke TW. Interaction of ofloxacin and warfarin. Ann Intern Med 1993; 119:1223.
49. Leor J, Levartowsky D, Sharon C. Interaction between nalidixic acid and warfarin [letter]. Ann Intern Med 1987, 107:601.
50. Toon S, Hopkins KJ, Garstang FM, Aarons L, Sedman A, Rowland M. Enoxacin-warfarin interaction: pharmacokinetic and stereo-chemical aspects. Clin Pharmacol Ther 1987; 42:33-41.
51. Niopas I, Toon S, Rowland M. Further insight into the stercoselective interaction between warfarin and cimetidine in man. Br J Clin Pharmacol 1991; 32:508-11.
52. Silver BA, Bell WR. Cimctidine potentiation of the hypothrombinemic effect of warfarin. Ann Intern Med 1979; 90:348-9.
53. Rocci ML, Vlasses PH, Distlerath LM, et al. Norfloxacin does not alter warfarin's disposition or anticoagulant effect J Clin Pharmacol 1990; 30:728-32.
54. Rindone JP, Jones WN, Garewal HS. Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin Clin Pharm 1991; 10: 136-8
55. Bianco TM, Bussey HI, Farnett LE, Linn WD, Roush MK, Wong YWJ Potential warfarin-ciprofloxacin interaction in patients receiving long term anticoagulation. Pharmacotherapy 1992; 12:435-9.
56. Racicwicz AM, Morgan PJ. Ranitidine-warfarin interaction [letter] Ann Intern Med 1990; 112:76-7.
57. Rosenthal AR, Self TH, Baker ED, Linden RA. Interaction of isoniazid and warfarin JAMA 1977; 238-2177.
58. Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989; 46.700-5.
59. Sahai J, Gallicano K, Olivcras L, et al. Cations in the didanosine tablet reduce ciprofloxacin bioavailability Clin Pharmacol Ther 1993; 53:292-7.
60. Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother 1990; 34: 432-5.
61. Grasela TH, Schentag JJ, Sedman AJ, et al. Inhibition of enoxacin absorption by antacids or ranitidine, Antimicrob Agents Chemother 1989; 33:615-7.
62. Flor S, Guay DRP, Opsahl JA, et al. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother 1990; 34:2436-8.
63. Lomaestro BM, Bailie GR. Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1991; 35.1004-7.
64. Neuvonen PJ, Kivisto KT, Lehto P. Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther 1991, 50:498-502.
65. Garrelts JC, Godley PJ, Petcrie JD, et al. Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob Agents Chemother 1990; 34:931-3.
66. Nix DE, Watson WA, Handy L, et al. The effect of sucralfate prctreatment on the pharrnacokinetics of ciprofloxacin. Pharmacotherapy 1989, 9:377-80.
67. Parpia SH, Nix DH, Hejmanowski LG, et al. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother 1989, 33-99-102.
68. Polk RE, Healy DP, Sahai J, et al. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers Antimicrob Agents Chemother 1989; 33:1841-4
69. Kara M, Hasinoff BB, McKay DW, et al. Clinical and chemical interactions between iron preparations and ciprofloxacin Br J Clin Pharmacol 1991; 31-257-61.
70. Mueller BA, Brierton DG, Abel SR, et al. Effect of enterai feeding with Ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1994; 38:2101-5